Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018

November 13, 2018 — A study in the current edition of the...

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018

November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE)...

Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018

November 1, 2018 — A vaccine may one day be able to replace...

Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018

October 31, 2018 — Amgen announced a new Repatha...

Rivaroxaban (Xeralto) is now cleared by the FDA with a new indication is for patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Technology | Antiplatelet and Anticoagulation Therapies | October 17, 2018

October 17, 2018 — The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban...

Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018

October 11, 2018 — Novel results from the landmark EMPA-REG OUTCOME...

 Pulmonary artery denervation for CpcPH from the PADN-5 trial. #TCT2017

A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.

News | Hypertension | October 04, 2018

October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and...

Videos | Left Atrial Appendage (LAA) Occluders | October 01, 2018

Ashish Pershad, M.D., medical director, structural heart program, Banner University Medical Heart Institute, Phoenix...

Antithrombin Drug Ineffective in Heart Failure With Sinus Rhythm and Coronary Disease
News | Heart Failure | September 07, 2018

September 7, 2018 — The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival,...

Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018

September 7, 2018 — A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science...

Tafamidis Improves Survival in Rare Heart Condition
News | Heart Failure | September 06, 2018

September 6, 2018 — Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart...

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018

September 4, 2018 — The jury is still out on whether people at moderate risk of a first heart attack or stroke...

Overlay Init